Alembic Pharmaceuticals Limited — Updates, 23-05-2025: Press Release

Alembic Pharmaceuticals received USFDA final approval for its Amlodipine-Atorvastatin combination tablets in multiple strengths, enhancing its US generic portfolio now totaling 223 ANDA approvals. This launch targets patients needing both blood pressure and cholesterol management, supporting deeper US market penetration and potential revenue growth. Alembic continues to leverage robust R&D and manufacturing strengths to expand its global generics footprint.